J&J's Ebola vaccine approved by EU

By The Science Advisory Board staff writers

July 1, 2020 -- Johnson & Johnson announced that the European Commission granted marketing authorization for its Janssen Pharmaceutical Ebola vaccine regimen for the prevention of Ebola virus disease.

The company worked with the World Health Organization on vaccine prequalification to accelerate the registration of the Ebola vaccine regimen in African countries and facilitate broad access to the vaccine.

The Ebola vaccine marks the first major regulatory approval of a vaccine developed by Janssen and is the first vaccine approved using the company's AdVac technology platform. This technology is currently being employed to develop vaccines against SARS-CoV-2, Zika, respiratory syncytial virus, and HIV.

The approved two-dose regimen includes adenovirus serotype 26 (Ad26).Zebov as an initial dose, based on Janssen's AdVac viral vector technology, and modified vaccinia virus Ankara-Bavarian Nordic (MVA-BN)-Filo as a second dose, based on Bavarian Nordic's MVA-BN technology, eight weeks later. To date, over 60,000 people have been dosed with Janssen's vaccine as part of clinical trials and vaccination initiatives.

The company has initiated discussions with the U.S. Food and Drug Administration to define required data for filing U.S. licensure.

City of Hope sponsors COVID-19 research
City of Hope released details of multiple COVID-19 research projects, including the development of two potential vaccines, new therapies, and better screening...
J&J announces manufacturing collaboration for COVID-19 vaccine
Johnson & Johnson, a Janssen Pharmaceuticals company, announced on April 24 a collaboration with Emergent BioSolutions to support the manufacturing...
J&J seeks to release COVID-19 vaccine by 2021
Johnson & Johnson has selected a lead COVID-19 vaccine candidate from a number of options it has been working on since January. The company hopes...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter